- Home
- PPBT vs PMAX Comparison
PPBT vs PMAX Comparison
Compare PPBT & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPBT | PMAX |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | Israel | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.7M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PPBT | PMAX |
|---|---|---|
| Price | $1.62 | $1.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 28.2K | ★ 47.3K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.20 |
| 52 Week High | $5.18 | $5.20 |
Technical Indicators
Market Signals| Indicator | PPBT | PMAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 33.22 |
| Support Level | $1.38 | $0.24 |
| Resistance Level | $1.85 | $2.69 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 87.02 | 28.57 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
About PMAX Powell Max Limited
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.